Pulmonary Cell News Volume 10.49 | Dec 9 2021

    By
    Justin.choi
    -
    0
    27






    2021-12-09 | PULCN 10.49


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 10.49 – 9 December, 2021
    TOP STORY

    Delayed Induction of Type I and III Interferons Mediates Nasal Epithelial Cell Permissiveness to SARS-CoV-2

    Scientists applied single-cell RNA sequencing and proteomics to a primary cell model of human nasal epithelium differentiated at air-liquid interface. SARS-CoV-2 demonstrated widespread tropism for nasal epithelial cell types.
    [Nature Communications]

    Full ArticlePress Release


    Register for the Respiratory Viruses: New Frontiers conference.
    PUBLICATIONSRanked by the impact factor of the journal

    Novel Proteinase-Activated Receptor-2 (PAR2) Antagonist C391 Inhibits Alternaria-Induced Human Airway Epithelial Signaling In Vitro and Asthma Indicators in Acute Exposure Murine Models

    Investigators developed C391, a potent proteinase-activated receptor-2 (PAR2) antagonist effective in blocking peptidomimetic- and trypsin-induced PAR2 signaling in vitro as well as reducing inflammatory PAR2-associated pain in vivo.
    [British Journal of Pharmacology]

    Abstract

    The Protective Effects of Omarigliptin against Lipopolysaccharide (LPS)- Induced Inflammatory Response and Expression of Mucin 5AC (MUC5AC) in Human Bronchial Epithelial Cells

    Researchers investigated whether Omarigliptin possessed a beneficial effect against LPS-induced injuries in human BEAS-2B bronchial epithelial cells.
    [Molecular Immunology]

    Abstract

    Budesonide Promotes Airway Epithelial Barrier Integrity Following Double-Stranded RNA Challenge

    The authors tested three classes of drugs commonly prescribed to treat asthma for their ability to promote barrier function using a cell culture model of virus-induced airway epithelial barrier disruption.
    [PLoS One]

    Full Article

    Oncogenic Dependency on STAT3 Serine Phosphorylation in KRAS Mutant Lung Cancer

    Researchers demonstrated that lung adenocarcinoma was suppressed in oncogenic KrasG12D-driven mouse models engineered for pS727-STAT3 deficiency.
    [Oncogene]

    Abstract

    Early Identification of Disease Progression in ALK-Rearranged Lung Cancer Using Circulating Tumor DNA Analysis

    Investigators utilized 343 longitudinal plasma DNA samples from 43 ALK alterations NSCLC patients receiving ALK-directed therapies to determine molecular progression based on matched panel-based targeted next-generation sequencing, and shallow whole-genome sequencing.
    [npj Precision Oncology]

    Full Article

    Targeting Senescence-Like Fibroblasts Radiosensitizes Non-Small Cell Lung Cancer and Reduces Radiation-Induced Pulmonary Fibrosis

    Scientists identified the senescence-like characteristics of cancer-associated fibroblasts (CAFs) after RT and clarify the formidable ability of senescence-like CAFs in promoting NSCLC cell proliferation and radioresistance through the JAK/STAT pathway.
    [JCI Insight]

    Full ArticleGraphical Abstract

    BIX01294 Inhibits EGFR Signaling in EGFR-Mutant Lung Adenocarcinoma Cells through a BCKDHA-Mediated Reduction in the EGFR Level

    The authors reported that BIX01294 (BIX) induced apoptotic cell death in EGFR-mutant NSCLC cells but not in their wild-type counterparts. Treatment with BIX resulted in a significant reduction in the EGFR level and inhibition of EGFR signaling only in EGFR-mutant NSCLC cells, leading to apoptosis.
    [Experimental & Molecular Medicine]

    Full Article

    Tanshinone IIA Suppresses the Progression of Lung Adenocarcinoma through Regulating CCNA2-CDK2 Complex and AURKA/PLK1 Pathway

    In vitro experimentas focused on the anti-lung adenocarcinoma (LUAD) effects and mechanisms of Tanshinone IIA on LUAD cells via MTT, plate cloning, Annexin V-FITC and PI dual staining, flow cytometry, and western blot assays.
    [Scientific Reports]

    Full Article

    An informative, visually-compelling wallchart detailing the organization and biology of the respiratory system. Request your copy.
    REVIEWS

    Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19

    Scientists describe alveolar and endothelial injury dynamics and associations with COVID-19 severity, cardiorenovascular injury, and outcomes.
    [American Journal of Respiratory and Critical Care Medicine]

    Abstract

    INDUSTRY AND POLICY NEWS

    Checkpoint Therapeutics Announces Initiation of CONTERNO Phase III Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

    Checkpoint Therapeutics, Inc. announced the initiation of the CONTERNO study, a global, randomized Phase III trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer.
    [Checkpoint Therapeutics. Inc. (GlobenewsWire, Inc.)]

    Press Release

    FEATURED EVENT

    Respiratory Viruses: New Frontiers

    January 17 – 20, 2022
    Keystone, Colorado, United States & Online

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Molecular Biology

    National Institutes of Health – Bethesda, Maryland, United States

    Associate/Full Professor of Medicine – Pulmonary

    Indiana University School of Medicine – Indianapolis, Indiana, United States

    Postdoctoral Position – Lung Disease

    Brigham and Women’s Hospital – Boston, Massachusetts, United States

    Postdoctoral Fellowship – Cardiovascular Sciences

    Medical College of Wisconsin – Milwaukee, Wisconsin, United States

    Faculty Position – Pediatric Asthma Research

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter